Login / Signup

Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT.

Tomasz CzerwMyriam LabopinSebastian GiebelGérard SociéLiisa VolinNathalie FegueuxTamás MassziDidier BlaiseSridhar ChagantiJan J CornelissenJakob PasswegJohan MaertensMaija Itälä-RemesDepei WuMohamad MohtyArnon Nagler
Published in: Cancer (2018)
Patients with Ph-neg ALL treated with allo-PBSCT benefit from the use of ATG in terms of improved GRFS. Its use may, therefore, be considered in this setting. Cancer 2018;124:2523-33. © 2018 American Cancer Society.
Keyphrases
  • stem cell transplantation
  • acute lymphoblastic leukemia
  • papillary thyroid
  • high dose
  • peripheral blood
  • squamous cell
  • bone marrow
  • lymph node metastasis
  • free survival
  • low dose
  • squamous cell carcinoma
  • young adults